Genmab (GMAB) Revenue & Revenue Breakdown
Genmab Revenue Highlights
Latest Revenue (Y)
$16.47B
Latest Revenue (Q)
$4.14B
Genmab Revenue by Period
Genmab Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $16.47B | 12.87% |
| 2022-12-31 | $14.60B | 72.07% |
| 2021-12-31 | $8.48B | -16.11% |
| 2020-12-31 | $10.11B | 88.43% |
| 2019-12-31 | $5.37B | 77.38% |
| 2018-12-31 | $3.03B | 27.89% |
| 2017-12-31 | $2.37B | 30.25% |
| 2016-12-31 | $1.82B | 60.29% |
| 2015-12-31 | $1.13B | 33.24% |
| 2014-12-31 | $850.38M | 28.15% |
| 2013-12-31 | $663.57M | 36.92% |
| 2012-12-31 | $484.64M | 38.10% |
| 2011-12-31 | $350.94M | -39.71% |
| 2010-12-31 | $582.08M | -0.68% |
| 2009-12-31 | $586.08M | -21.34% |
| 2008-12-31 | $745.11M | 40.71% |
| 2007-12-31 | $529.54M | 290.67% |
| 2006-12-31 | $135.55M | 37.60% |
| 2005-12-31 | $98.50M | 2301.98% |
| 2004-12-31 | $4.10M | -94.00% |
| 2003-12-31 | $68.33M | 100.00% |
| 2002-12-31 | - | - |
Genmab generated $16.47B in revenue during NA 2023, up 12.87% compared to the previous quarter, and up 544.57% compared to the same period a year ago.
Genmab Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $4.14B | -11.44% |
| 2023-12-31 | $4.68B | -1.39% |
| 2023-09-30 | $4.74B | 13.01% |
| 2023-06-30 | $4.20B | 47.09% |
| 2023-03-31 | $2.85B | -45.40% |
| 2022-12-31 | $5.23B | 27.89% |
| 2022-09-30 | $4.09B | 29.25% |
| 2022-06-30 | $3.16B | 49.22% |
| 2022-03-31 | $2.12B | -19.09% |
| 2021-12-31 | $2.62B | 13.38% |
| 2021-09-30 | $2.31B | 17.14% |
| 2021-06-30 | $1.97B | 24.73% |
| 2021-03-31 | $1.58B | -22.65% |
| 2020-12-31 | $2.04B | 18.56% |
| 2020-09-30 | $1.72B | -68.37% |
| 2020-06-30 | $5.45B | 511.10% |
| 2020-03-31 | $892.00M | -69.88% |
| 2019-12-31 | $2.96B | 184.78% |
| 2019-09-30 | $1.04B | 34.36% |
| 2019-06-30 | $773.91M | 30.95% |
| 2019-03-31 | $591.01M | -52.18% |
| 2018-12-31 | $1.24B | 106.46% |
| 2018-09-30 | $598.60M | 17.45% |
| 2018-06-30 | $509.68M | -25.16% |
| 2018-03-31 | $681.01M | -33.09% |
| 2017-12-31 | $1.02B | 214.69% |
| 2017-09-30 | $323.45M | -58.18% |
| 2017-06-30 | $773.35M | 208.38% |
| 2017-03-31 | $250.78M | -72.96% |
| 2016-12-31 | $927.46M | 154.33% |
| 2016-09-30 | $364.66M | 3.06% |
| 2016-06-30 | $353.83M | 107.92% |
| 2016-03-31 | $170.17M | -70.39% |
| 2015-12-31 | $574.66M | 106.89% |
| 2015-09-30 | $277.76M | 59.78% |
| 2015-06-30 | $173.84M | 62.81% |
| 2015-03-31 | $106.78M | -50.52% |
| 2014-12-31 | $215.80M | -20.52% |
| 2014-09-30 | $271.52M | 134.09% |
| 2014-06-30 | $115.99M | -53.06% |
| 2014-03-31 | $247.07M | 14.36% |
| 2013-12-31 | $216.04M | 44.35% |
| 2013-09-30 | $149.66M | 8.38% |
| 2013-06-30 | $138.09M | -13.57% |
| 2013-03-31 | $159.78M | -2.04% |
| 2012-12-31 | $163.10M | 40.76% |
| 2012-09-30 | $115.88M | 3.79% |
| 2012-06-30 | $111.65M | 18.76% |
| 2012-03-31 | $94.01M | 1.01% |
| 2011-12-31 | $93.07M | 2.42% |
| 2011-09-30 | $90.87M | 8.33% |
| 2011-06-30 | $83.88M | 0.91% |
| 2011-03-31 | $83.12M | -8.81% |
| 2010-12-31 | $91.16M | -57.52% |
| 2010-09-30 | $214.60M | 26.38% |
| 2010-06-30 | $169.80M | 59.41% |
| 2010-03-31 | $106.52M | -44.78% |
| 2009-12-31 | $192.90M | 179.45% |
| 2009-09-30 | $69.03M | -6.94% |
| 2009-06-30 | $74.17M | -70.33% |
| 2009-03-31 | $249.98M | - |
Genmab generated $4.14B in revenue during Q1 2024, up -11.44% compared to the previous quarter, and up 79.26% compared to the same period a year ago.
Genmab Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| GMAB | Genmab | $16.47B | $4.14B |
| BGNE | BeiGene | $2.46B | $929.17M |
| AMLX | Amylyx Pharmaceuticals | $380.79M | $416.00K |
| APLS | Apellis Pharmaceuticals | $366.28M | $176.57M |
| LEGN | Legend Biotech | $285.14M | $93.99M |
| ASND | Ascendis Pharma | $266.72M | $95.89M |
| BPMC | Blueprint Medicines | $249.38M | $128.18M |
| TVTX | Travere Therapeutics | $145.24M | $62.90M |
| ALEC | Alector | $97.06M | $15.08M |
| CYTK | Cytokinetics | $7.53M | $463.00K |
| PCVX | Vaxcyte | - | - |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| TERN | Terns Pharmaceuticals | - | - |
| AKRO | Akero Therapeutics | - | - |
| EWTX | Edgewise Therapeutics | - | - |